The Russian Sovereign Fund (RDIF), which financed the development of the vacuna Sputnik V, is now contributing to clinical trials of a vaccine “Light” less effective than the first, and that instead of two administrations requires only one.
While with the vaccine Sputnik V can be 90% effective against the coronavirus, according to Russian officials, the efficiency in the case of the “light” version is lower and can reach 85% in some cases, and less in others, had advanced Kirill Dmitriev, president of the RDIF.
This vaccine “It could become an effective temporary solution for several countries that have reached a peak in the disease … and are trying to save as many lives as possible”noted the senior Russian official.
However, for the Russian market, Sputnik V in two doses will continue to be the main vaccine used in the framework of a large vaccination campaign started in December by the authorities, according to the RDIF.
Last August, Russia was the first country in the world to authorize a coronavirus vaccine, prompting a lot of international criticism as a premature announcement, ahead of phase 3 testing and the publication of scientific results. Sputnik V has been authorized in their territories by other countries, such as Belarus, Argentina, Algeria, Bolivia and Serbia, the RDIF indicated.
For their part, Palestinian authorities have also given their authorization to administer this vaccine to their population, the RDIF congratulated itself on Monday in a separate statement, clarifying that the first doses could be delivered within a month.
“We are happy that Sputnik V is now present not only in Europe, Africa, Asia and Latin America, but also in the Middle East,” stressed Dmitriev.
About 1.5 million people worldwide were inoculated with Sputnik V to date, according to the RDIF. In Argentina, until January 8, some 107,000 people received the first dose while the Government plans to delay the massive application of the second in order to increase the number of vaccinated.
HV / DS